Biotechnology

Vericel

Vericel released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 68.43 M (forecast USD 63.62 M), actual EPS USD -0.1241 (forecast USD -0.1537)

Vericel to Release FY2026 Q1 Earnings on May 7, Pre-Market EST; Forecast Revenue USD 63.62 M, EPS USD -0.1537

Vericel released FY2025 annual earnings on February 26 Pre-Market (EST), actual revenue USD 276.26 M (forecast USD 276.01 M), actual EPS USD 0.32 (forecast USD 0.2614)

Vericel released FY2025 Q4 earnings on February 26 Pre-Market EST, actual revenue USD 92.92 M (forecast USD 92.66 M), actual EPS USD 0.4459 (forecast USD 0.39)

Vericel to release FY2025 Q4 earnings on February 26, pre-market EST, with forecasted revenue of USD 92.66 M and EPS of USD 0.39

Vericel released FY2025 Q3 earnings on November 6 During-Market EST, actual revenue USD 67.5 M (forecast USD 64.53 M), actual EPS USD 0.1 (forecast USD -0.0062)

Vericel released FY2025 9 Months Earnings on November 6 During-Market EST, with actual revenue of USD 183.34 M and EPS of USD -0.1409

Josh Jennings Maintains Buy Rating on Vericel

Vericel to release FY2025 Q3 earnings on November 6 During-Market EST, forecast revenue USD 64.53 M, EPS USD -0.0062

Vericel Reports 20% Year-over-Year Q2 Revenue Growth to 63.2 Million USD

Vericel released FY2025 Semi-Annual earnings on July 31 Pre-Market EST, actual revenue USD 115.84 M, actual EPS USD -0.24

Vericel released FY2025 Q2 earnings on July 31 Pre-Market (EST), actual revenue USD 0 (forecast USD 64.49 M), actual EPS USD 0 (forecast USD -0.0312)

Vericel to Release FY2025 Q2 Earnings on July 31 Pre-Market EST, Forecast Revenue USD 64.49M, EPS USD -0.0312

Vericel Corporation to Release Q2 2025 Earnings

New York State Common Retirement Fund Increases Holdings in Vericel Corporation

Principal Financial Group Inc. Increases Holdings in Vericel Corporation

Vericel Corporation Upgraded to Neutral Rating

UBS AM Increases Stake in Vericel

Vericel Releases Financial Status and Market Expansion Plans

Stephens &amp; Co. reiterates Vericel's rating and target price

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

VCEL

Truist Financial Corp reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 59.9% in Q4, now holding 24,763 shares valued at $892,000. Other investors, including AQR Capital and Goldman Sachs, adjusted their positions as well. Analysts have mixed ratings on VCEL, with a consensus rating of 'Moderate Buy' and an average price target of $55.40. Vericel reported a quarterly EPS of ($0.12), exceeding estimates, with revenue up 30.1% year-over-year.

Market Beat

Truist Financial

Goldman Sachs

GS Hldg R

Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp

Vericel Corporation's Independent Director, Paul Wotton, sold 35% of his shares, worth $327k at $32.74 each, marking the largest insider sale in the past year. This sale occurred below the current stock price of $33.14, raising questions about insider sentiment on the stock's valuation. Despite this, insiders own 1.2% of Vericel shares, indicating some alignment with shareholders, though no insider purchases have been reported in the last twelve months.

Simplywall

Vericel Independent Director Paul Wotton Sells 35% Of Holding

Vericel (VCEL) shares have declined about 5% in the past month and 6% over the last three months, closing at $33.46. Analysts suggest a fair value of $64.00, indicating the stock may be undervalued despite a high P/E ratio of 79.6x, significantly above industry averages. The company plans to expand its MACI product outside the U.S., which could enhance revenue. However, risks include potential reimbursement issues and the effectiveness of new investments. Investors are advised to consider the gap between optimistic growth narratives and current valuations before making decisions.

Assessing Vericel (VCEL) Valuation After Recent Share Price Weakness And Contrasting Growth Narratives

Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, driven by strong growth in its MACI cartilage repair franchise and Burn Care business, along with anticipated NexoBrid procurement revenue from a new federal contract. CEO Nick Colangelo highlighted the company's outstanding financial and commercial results during the earnings call.

Vericel Q1 earnings call highlights

Vericel Corporation forecasts 2026 revenue between $326M and $336M, driven by a strong Q1 performance with record revenue of over $68M, a 30% increase year-over-year. The company raised its full-year guidance due to expected BARDA-backed NexoBrid procurement revenue starting in H2. Key milestones include FDA approval for MACI manufacturing, enhancing capacity for potential international sales. The company anticipates gross margins around 75% and adjusted EBITDA margins of approximately 27%. Q2 MACI revenue is projected at $62.5M to $63.5M, with Burn Care revenue expected at $9M to $10M.

Vericel forecasts $326M-$336M 2026 revenue as BARDA-backed NexoBrid procurement begins in H2

Vericel (NASDAQ:VCEL) reported quarterly earnings of ($0.12) EPS, beating estimates by $0.03. Revenue reached $68.43 million, exceeding expectations of $63.68 million, marking a 30.1% year-over-year increase. The company raised its 2026 revenue guidance to $326M–$336M. Despite strong financials, Vericel's stock fell 4.5% to $35.13. Analysts maintain a "Moderate Buy" rating with an average price target of $55.40. Insider Jonathan Mark Hopper sold shares, reducing his stake by 4.39%.

HSBC

HSBC HOLDINGS

HSBC Holdings Plc

HSBC 5xShortSG241213

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

Earnings Watch

Vericel | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 68.43 M

Vericel(VCEL.US)